Oral contraceptive use for the primary prevention of ovarian cancer.
Havrilesky LJ, Gierisch JM, Moorman PG, Coeytaux RR, Urrutia RP, Lowery WJ, Dinan M, McBroom AJ, Wing L, Musty MD, Lallinger KR, Hasselblad V, Sanders GD, Myers ER. Oral contraceptive use for the primary prevention of ovarian cancer. Evidence Report Technology Assessment 2013, 1-514. PMID: 24423062, PMCID: PMC4781074.Peer-Reviewed Original ResearchConceptsOvarian cancer preventionOral contraceptivesVascular eventsOvarian cancerOC useOC usersPrimary preventionHarm/benefit ratioCervical cancerColorectal cancerCancer incidenceCancer preventionUse of OCsPersistent human papillomavirus (HPV) infectionCurrent OC usersBenefit ratioHuman papillomavirus infectionOral contraceptive useBreast cancer incidenceOvarian cancer incidenceLife expectancyOvarian cancer outcomeRisk of breastRandom-effects modelEnglish-language studies